Natco Pharma: Announcement under Regulation 30 (LODR)-Change in Directorate | Value Research

Natco Pharma: Announcement under Regulation 30 (LODR)-Change in Directorate

On the basis of the recommendations of Nomination & Remuneration Committee in its meeting held today the Board of Directors have co-opted Dr. Pavan Ganapati Bhat (DIN: 09691260) as an Additional Director and appointed him as an Executive Director i.e. Director & Executive Vice President (Technical Operations) of the Company for a period of 2 (two) years w.e.f. 9th August 2022 subject to approval of the members of the Company at the ensuing Annual General Meeting. Brief Profile of Dr. Pavan Ganapati Bhat in terms of the SEBI Listing Regulations is annexed herewith as Annexure - 1.

Click here to view PDF


Other Categories